U.S. markets open in 1 hour 36 minutes
  • S&P Futures

    3,753.75
    -3.00 (-0.08%)
     
  • Dow Futures

    30,010.00
    +28.00 (+0.09%)
     
  • Nasdaq Futures

    11,497.75
    -44.00 (-0.38%)
     
  • Russell 2000 Futures

    1,760.20
    +2.10 (+0.12%)
     
  • Crude Oil

    89.48
    +1.03 (+1.16%)
     
  • Gold

    1,715.40
    -5.40 (-0.31%)
     
  • Silver

    20.70
    +0.05 (+0.22%)
     
  • EUR/USD

    0.9795
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    3.8260
    0.0000 (0.00%)
     
  • Vix

    30.41
    +1.86 (+6.51%)
     
  • GBP/USD

    1.1196
    +0.0027 (+0.24%)
     
  • USD/JPY

    144.9410
    -0.1270 (-0.09%)
     
  • BTC-USD

    19,995.11
    -213.74 (-1.06%)
     
  • CMC Crypto 200

    454.77
    -8.35 (-1.80%)
     
  • FTSE 100

    7,004.77
    +7.50 (+0.11%)
     
  • Nikkei 225

    27,116.11
    -195.19 (-0.71%)
     

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference

·1 min read
Baudax Bio, Inc.
Baudax Bio, Inc.

MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the 24th Annual H.C. Wainwright Healthcare Conference, taking place in New York, New York on Wednesday, September 14, 2022 at 3:00 p.m. Eastern Time.

A webcast of the presentation will be available on the “Events” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The webcast will be archived on the company’s website for 90 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. Baudax Bio markets ANJESO®, the first and only 24-hour, non-opioid, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two clinical-stage, novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

CONTACT:

Investor Relations Contact:

Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:

Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com